PRESS RELEASE published on 09/03/2024 at 14:30, 1 year 9 months ago Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1 MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF published on 09/02/2024 at 13:05, 1 year 9 months ago Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1 COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1
BRIEF published on 09/02/2024 at 13:05, 1 year 9 months ago La FDA de Taïwan approuve le vaccin COVID-19 de Moderna ciblant la variante JN.1 du SRAS-CoV-2 Moderne Vaccin Contre Le Covid-19 Spikevax SARS-CoV-2 JN.1 FDA De Taïwan
PRESS RELEASE published on 09/02/2024 at 13:00, 1 year 9 months ago Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 Moderna receives approval for updated COVID-19 vaccine formulation targeting SARS-CoV-2 variant JN.1 from Taiwan FDA. Regulatory decisions globally expected soon COVID-19 Vaccine Moderna Spikevax SARS-CoV-2 Variant Taiwan FDA
BRIEF published on 08/29/2024 at 14:05, 1 year 9 months ago Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination COVID-19 Moderna Vaccination Health Campaign Public Awareness
BRIEF published on 08/29/2024 at 14:05, 1 year 9 months ago Moderna lance une campagne nationale de sensibilisation pour favoriser la vaccination contre la COVID-19 Moderne COVID 19 Vaccination Campagne De Santé Sensibilisation Du Public
PRESS RELEASE published on 08/29/2024 at 14:00, 1 year 9 months ago Moderna Launches National Awareness Campaign to Help Drive COVID-19 Vaccination Moderna launches 'Do It For You & Them' campaign to drive vaccination rates in the U.S. and inform about COVID-19 risks & impact, updated vaccines available for KP.2 variant COVID-19 Moderna Awareness Campaign KP.2 Variant Vaccination Rates
BRIEF published on 08/23/2024 at 13:05, 1 year 9 months ago Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R) Public Health European Commission MRNA Technology RSV Vaccine Moderna Approval
BRIEF published on 08/23/2024 at 13:05, 1 year 9 months ago Moderna reçoit l'approbation de la Commission européenne pour son vaccin contre le VRS mRESVIA(R) Santé Publique Vaccin Contre Le VRS Commission Européenne Technologie De L'ARNm Approbation De Moderna
PRESS RELEASE published on 08/23/2024 at 13:00, 1 year 9 months ago Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R) Moderna receives European Commission approval for mRESVIA(R) (mRNA-1345) vaccine to fight RSV in adults aged 60+; significant breakthrough beyond COVID-19 European Commission Moderna Vaccine RSV MRESVIA
Published on 06/20/2026 at 01:00, 1 day 18 hours ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 1 day 19 hours ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 2 days 15 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 2 days 18 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 2 days 18 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 21:25, 22 hours 12 minutes ago VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 1 day 13 hours ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 1 day 23 hours ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 1 day 23 hours ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 2 days ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 2 days ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 2 days ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 2 days ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 2 days ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
